Thursday, 5 December 2013

GAD-treatment of children and adolescents with recent-onset Type 1 diabetes preserves residual insulin secretion after 30?months

Treatment with two doses of GAD-alum in children and adolescents with recent-onset T1D shows no adverse events and preserves residual insulin secretion (Diabetes/Metabolism Research and Reviews)


Assessing the cost-effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy Model

This paper describes the conceptual modelling, model implementation and model validation of the Sheffield Type 1 Diabetes Policy Model (version 1.0), developed through funding by the UK National Institute for Health Research as part of the Dose Adjustment for Normal Eating research programme (Diabetic Medicine)

No comments:

Post a Comment